| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 4 | 2 | 2 | 14 | 18 | 27 | 23 | 37 | 44 | 42 | 45 | 47 |
| Expenses | 24 | 10 | 13 | 19 | 17 | 17 | 16 | 19 | 22 | 24 | 29 | 31 |
| EBITDA | -20 | -8 | -10 | -6 | 1 | 10 | 7 | 18 | 22 | 18 | 16 | 16 |
| Operating Profit % | -492 % | -373 % | -462 % | -71 % | -27 % | 35 % | 28 % | 48 % | 49 % | 42 % | 33 % | 22 % |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 7 | 7 | 7 | 7 | 7 | 7 |
| Interest | 7 | 8 | 8 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 10 | 15 | 11 | 11 | 9 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | 3 | 3 | 5 | 1 |
| Net Profit | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 22 | 12 | 8 | 6 | 3 |
| EPS in ₹ | -8.83 | -5.56 | -5.77 | -2.24 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 0.92 | 0.50 |
Zenotech Laboratories
Zenotech Laboratories
47.90
-0.81
(-1.66%)
Market Cap
₹- Cr
PE Ratio
-
Volume
14,082.00
Day High - Low
₹48.85 - ₹46.00
52W High-Low
₹77.75 - ₹47.50
Key Fundamentals
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
15.77
EBITDA
-
Dividend Yield
- %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
-
Actual
Company News
View All News
Zenotech Laboratories Limited held a Board of Directors meeting on October 31, 2025, approving unaudited standalone financial results for the quarter and half-year ended September 30, 2025. The company reported revenue from operations of Rs. 1,023.19 lakhs for the quarter, compared to Rs. 874.60 lakhs in the same period last year. For the half-year, revenue reached Rs. 1,887.10 lakhs versus Rs. 1,764.09 lakhs previously. The company recorded a profit before tax of Rs. 120.85 lakhs for the quarter. Total assets stood at Rs. 10,892.39 lakhs as of September 30, 2025. The company reversed excess provision of Rs. 4.97 lakhs related to export obligation settlement, reported as exceptional items. Additionally, accounting adjustments of Rs. 190.49 lakhs were made for tax liabilities under section 115BAA of the Income Tax Act. The financial results underwent limited review by statutory auditors and were approved by the Audit Committee.
Zenotech Laboratories Limited approved its unaudited standalone financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs 863.91 lakhs compared to Rs 889.49 lakhs in the same quarter last year, while total income remained relatively stable at Rs 1,023.16 lakhs versus Rs 1,024.96 lakhs. Net profit for the quarter was Rs 98.96 lakhs, down from Rs 128.97 lakhs in the corresponding quarter of the previous year. Earnings per share stood at Rs 0.16 compared to Rs 0.21 in the same period last year. The Board also approved the appointment of M/s. G S K A & Co. as new statutory auditors for a five-year term, replacing M/s. PKF Sridhar & Santhanam LLP who will complete their two consecutive terms. The appointment is subject to shareholder approval at the 36th Annual General Meeting scheduled for September 26, 2025. The company operates solely in the pharmaceuticals segment and generates other operating income through rentals for biotech facility and equipment leased to Sun Pharmaceutical Industries Limited.
Zenotech Laboratories: Q3 Profit Drops 49.7% Despite Revenue GrowthJan 30, 2025
Zenotech Laboratories reported Q3 FY25 results with revenue up 2.74% YoY to ₹11.24 crore, but profit fell 49.7% YoY to ₹1.69 crore. EPS decreased 60% to ₹0.22. Operating income rose 35.82% QoQ but declined 22.44% YoY.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
230.55 | #1 508.40 | #1 - | #1 105.00 | - | #1 13 | - | 61.67 | |
83.95 | 97.90 | #1 - | 57.50 | - | 7 | - | 58.08 | |
903.00 | - | #1 - | - | - | - | - | 46.51 | |
110.00 | - | #1 - | - | - | - | - | 46.59 | |
72.48 | - | #1 - | - | - | - | - | 91.06 | |
77.00 | - | #1 - | - | - | - | - | 42.42 | |
24.71 | - | #1 - | - | - | - | - | 46.91 | |
137.00 | - | #1 - | - | - | - | - | 45.14 | |
0.68 | - | #1 - | - | - | - | - | 32.95 | |
47.90 | - | #1 - | - | - | - | - | 38.44 |
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 94 | 101 | 106 | 111 |
| Fixed Assets | 52 | 48 | 47 | 44 | 43 | 49 | 74 | 71 | 65 | 66 | 61 |
| Current Assets | 9 | 3 | 2 | 31 | 19 | 6 | 7 | 7 | 16 | 26 | 36 |
| Capital Work in Progress | 0 | 0 | 0 | 2 | 17 | 29 | 2 | 0 | 5 | 2 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 5 | 4 | 35 | 25 | 8 | 9 | 23 | 31 | 39 | 47 |
| Total Liabilities | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 94 | 101 | 106 | 111 |
| Current Liabilities | 91 | 99 | 116 | 39 | 45 | 35 | 15 | 16 | 17 | 14 | 13 |
| Non Current Liabilities | 0 | 0 | 0 | 0 | 0 | 1 | 23 | 8 | 2 | 2 | 2 |
| Total Equity | -27 | -46 | -66 | 42 | 39 | 50 | 48 | 71 | 82 | 91 | 96 |
| Reserve & Surplus | -62 | -81 | -100 | -19 | -22 | -11 | -13 | 10 | 21 | 30 | 35 |
| Share Capital | 34 | 34 | 34 | 61 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | -0 | 0 | 28 | -15 | -12 | 1 | 0 | 9 | -9 | 25 |
| Investing Activities | 0 | 6 | -1 | -3 | -16 | -21 | -5 | -2 | -6 | -21 | 15 |
| Operating Activities | -8 | -5 | 2 | -16 | -14 | 11 | 6 | 18 | 21 | 12 | 10 |
| Financing Activities | 7 | -1 | -1 | 47 | 15 | -3 | 0 | -16 | -6 | 0 | 0 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % | 68.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % | 0.98 % |
| Public / Retail | 26.40 % | 26.41 % | 26.42 % | 22.36 % | 22.47 % | 22.50 % | 22.84 % | 22.65 % | 22.67 % | 22.57 % | 22.50 % | 22.59 % | 22.65 % | 22.72 % | 22.66 % | 22.83 % | 22.78 % | 22.78 % | 22.80 % |
| Others | 4.75 % | 4.74 % | 4.73 % | 8.79 % | 8.68 % | 8.65 % | 7.34 % | 7.52 % | 7.50 % | 7.60 % | 7.67 % | 7.58 % | 7.52 % | 7.45 % | 7.51 % | 7.34 % | 7.39 % | 7.38 % | 7.36 % |
| No of Share Holders | 6,537 | 6,764 | 7,299 | 7,566 | 7,760 | 8,014 | 7,930 | 8,746 | 9,142 | 9,249 | 9,589 | 9,762 | 9,819 | 9,750 | 10,641 | 10,667 | 10,690 | 10,661 | 10,670 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Jun 2017 |  Rights | 17:22 | 01 Jun 2017 | 0.00 | 0.00 |
| 29 Sept 2023 |  Annual General Meeting | NA | 29 Sept 2023 | 54.21 | 55.62 |
| 27 Sept 2024 | Annual General Meeting | NA | 27 Sept 2024 | 64.37 | 93.12 |
| 23 Oct 2024 |  Quarterly Result Announcement | NA | 23 Oct 2024 | 92.56 | 84.33 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 63.02 | 59.29 |
| 25 Apr 2025 | Quarterly Result Announcement | NA | 25 Apr 2025 | 59.37 | 59.02 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 61.87 | 61.77 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 61.77 | 52.53 |
| 31 Oct 2025 | Quarterly Result Announcement | NA | 31 Oct 2025 | 49.65 | 53.00 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 01, 2025
Nov 01, 2025Board Meeting Outcome for Approval Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30 2025.Oct 31, 2025
Oct 31, 2025Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30 2025Oct 31, 2025
Oct 31, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30 2025Oct 22, 2025
Oct 22, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 29, 2025
Sep 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Sep 29, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Board Meeting Outcome for Updation Of Address Of The Registered Office Of The CompanySep 25, 2025
Sep 25, 2025Updation Of Address Of Registered Office Of The CompanySep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Sep 02, 2025Notice Of 36Th Annual General Meeting Of Zenotech Laboratories Limited.Sep 01, 2025
Sep 01, 2025Reg. 34 (1) Annual Report.Sep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Aug 29, 2025Intimation Of 36Th Annual General Meeting Of Zenotech Laboratories Limited (The Company).Aug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Jul 30, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On July 28 2025Jul 28, 2025
Jul 28, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On July 28 2025Jul 28, 2025
Jul 28, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Jul 28, 2025
Jul 28, 2025Board Meeting Intimation for Considering And Approving Unaudited Standalone Financial Results For The Quarter Ended June 30 2025.Jul 19, 2025
Jul 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 27, 2025
Apr 27, 2025Integrated Filing (Financial)Apr 26, 2025
Apr 26, 2025Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025Apr 25, 2025
Apr 25, 2025Audited Financial Results For The Quarter And Financial Year Ended March 31 2025Apr 25, 2025
Apr 25, 2025Board Meeting Intimation for Considering And Approving Audited Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025.Apr 21, 2025
Apr 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 30, 2025
Mar 30, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 15, 2025
Mar 15, 2025Integrated Filing (Financial)Feb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2025
Jan 30, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On January 28 2025Jan 28, 2025
Jan 28, 2025Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 28, 2025
Jan 28, 2025Board Meeting Intimation for Approval Of Financial Results For The Quarter And Nine Months Ended December 31 2024.Jan 18, 2025
Jan 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Jan 13, 2025Closure of Trading WindowDec 27, 2024
Dec 27, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Nov 07, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 24, 2024
Oct 24, 2024Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024 And Appointment Of Dr. Sachin Laxmanappa Gavandare As Chief Executive Officer (Key Managerial Personnel) Of The Company With Immediate Effect.Oct 23, 2024
Oct 23, 2024Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Oct 23, 2024
Oct 23, 2024Board Meeting Intimation for Consideration And Approval Of Financial ResultsOct 17, 2024
Oct 17, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 15, 2024
Oct 15, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 28, 2024
Sep 28, 2024Closure of Trading WindowSep 27, 2024
Sep 27, 2024Technical Indicators
RSI(14)
Neutral 42.41
ATR(14)
Less Volatile 1.56
STOCH(9,6)
Neutral 23.25
STOCH RSI(14)
Neutral 45.00
MACD(12,26)
Bearish -0.07
ADX(14)
Weak Trend 22.28
UO(9)
Bullish 29.67
ROC(12)
Downtrend And Accelerating -3.16
WillR(14)
Neutral -71.86
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
